Wissenschaftliche Arbeiten

Prof. Dr. İrfan Çiçin

345 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil
  1. Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients

    Journal of Men s Health, 2021

    DOI 10.31083/jomh.2021.041 5 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  2. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

    The Lancet, 2021

    DOI 10.1016/s0140-6736(21)00228-2 PMID 33581821 644 Zitationen (Europe PMC) Quelle: OpenAlex

  3. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer

    JAMA Oncology, 2021

    DOI 10.1001/jamaoncol.2021.3523 PMID 34473194 225 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  4. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.20.03579 PMID 33513313 204 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  5. A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer

    Clinical Lung Cancer, 2021

    DOI 10.1016/j.cllc.2021.04.005 PMID 34034991 39 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  6. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade

    British Journal of Cancer, 2021

    DOI 10.1038/s41416-021-01532-5 PMID 34621044 27 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  7. Prognostic nutritional index and its dynamics after curative treatment are independent prognostic factors on survival in non-metastatic nasopharyngeal carcinoma

    Supportive Care in Cancer, 2021

    DOI 10.1007/s00520-021-06627-6 PMID 34677649 14 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  8. Investigation of the relationship between GSTM1 gene variations and serum trace elements, plasma malondialdehyde levels in patients with colorectal cancer

    Molecular Biology Reports, 2021

    DOI 10.1007/s11033-021-06694-2 PMID 34498162 9 Zitationen (Europe PMC) Quelle: OpenAlex

  9. Secondary Pneumothorax During Immunotherapy in two Patients with Metastatic Solid Tumors; a New Entity

    Immunotherapy, 2021

    DOI 10.2217/imt-2020-0233 PMID 33820440 7 Zitationen (Europe PMC) Quelle: OpenAlex

  10. Nivolumab in Metastatic Renal Cell Carcinoma: Results from the Turkish Oncology Group Kidney Cancer Consortium Database

    Future Oncology, 2021

    DOI 10.2217/fon-2021-0717 PMID 34726480 7 Zitationen (Europe PMC) Quelle: OpenAlex

  11. An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

    European Journal of Breast Health, 2021

    DOI 10.4274/ejbh.galenos.2021.2021-9-9 PMID 35059593 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  12. Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?

    PubMed, 2021

    PMID 34761635 5 Zitationen (Europe PMC) Quelle: OpenAlex

  13. Prognostic Factors for Survival in Transverse Colon Cancers

    Journal of Gastrointestinal Cancer, 2021

    DOI 10.1007/s12029-021-00675-1 PMID 34302255 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  14. Nasal hemangiopericytoma presenting with oncogenic osteomalasia: A case report and literature review

    Current Problems in Cancer, 2021

    DOI 10.1016/j.currproblcancer.2020.100704 PMID 33446319 1 Zitation (Europe PMC) Quelle: OpenAlex

  15. Skeletal muscle loss during anti-epidermal growth factor receptor therapy is an independent prognostic factor on non-small cell lung cancer patients survival.

    PubMed, 2021

    PMID 34268945 2 Zitationen (Europe PMC) Quelle: OpenAlex

  16. Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma

    Tumori Journal, 2021

    DOI 10.1177/0300891621996448 PMID 33624577 2 Zitationen (Europe PMC) Quelle: OpenAlex

  17. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.

    PubMed, 2021

    PMID 34565028 2 Zitationen (Europe PMC) Quelle: OpenAlex

  18. Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.9085 9 Zitationen (OpenAlex) Quelle: OpenAlex

  19. Abstract CT179: Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer

    Cancer Research, 2021

    DOI 10.1158/1538-7445.am2021-ct179 10 Zitationen (OpenAlex) Quelle: OpenAlex

  20. Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.9038 3 Zitationen (OpenAlex) Quelle: OpenAlex

  21. Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.9078 3 Zitationen (OpenAlex) Quelle: OpenAlex

  22. Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.6_suppl.321 1 Zitation (OpenAlex) Quelle: OpenAlex

  23. Abstract OT-09-09: AMEERA-3, a phase 2 trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (her2−), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies

    Cancer Research, 2021

    DOI 10.1158/1538-7445.sabcs20-ot-09-09 Quelle: OpenAlex

  24. Metastatic cutaneous melanoma epidemiological registry in Turkey: A preliminary evaluation of diagnosis and treatment approaches

    Sakarya Üniversitesi Kurumsal Açık Akademik Arşivi, 2021

    Quelle: OpenAlex

  25. Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.e15561 Quelle: OpenAlex

  26. The relation between tissue galectin-3 level and platinum resistance in neoadjuvant bladder cancer treatment.

    PubMed, 2021

    PMID 34268970 Quelle: OpenAlex

  27. Distribution Data of Epidermal Growth Factor Receptor Mutations Detected by Next-Generation Sequencing Method in Non-Small Cell Lung Cancer

    Journal of Oncological Sciences, 2021

    DOI 10.37047/jos.2021-84407 Frei zugänglicher VolltextQuelle: OpenAlex

  28. Metastatic cutaneous melanoma epidemiological registry in Turkey: A preliminary evaluation of diagnosis and treatment approaches

    Bursa Uludag University - AVESIS, 2021

    Quelle: OpenAlex

  29. AMEERA-3, a phase 2 trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (her2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies

    Trakya University's Institutional Open Access System (Trakya University), 2021

    Quelle: OpenAlex

  30. PROGNOSTIC AND PREDICTIVE MARKERS OF FOLFIRI/AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER (TOG STUDY)

    AYBU AVESIS, 2020

    Quelle: OpenAlex

  31. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

    Lung Cancer, 2020

    DOI 10.1016/j.lungcan.2020.07.022 PMID 32799090 30 Zitationen (Europe PMC) Quelle: OpenAlex

  32. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.e13055 Quelle: OpenAlex

  33. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.20.02514 PMID 32954927 837 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  34. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

    The Lancet Oncology, 2020

    DOI 10.1016/s1470-2045(20)30539-8 PMID 33285097 584 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  35. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

    Journal of Thoracic Oncology, 2020

    DOI 10.1016/j.jtho.2020.06.015 PMID 32599071 504 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  36. Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study

    ESMO Open, 2020

    DOI 10.1136/esmoopen-2020-000698 PMID 32487542 30 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  37. Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155219900908 PMID 32054412 9 Zitationen (Europe PMC) Quelle: OpenAlex

  38. Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak

    Turkish Journal of Surgery, 2020

    DOI 10.5578/turkjsurg.4815 PMID 33015560 7 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  39. Clinicopathological and prognostic characteristics of acral metastases in patients with malignant disease: A retrospective study

    Acta Orthopaedica et Traumatologica Turcica, 2020

    DOI 10.5152/j.aott.2020.20052 PMID 33650515 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  40. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.

    PubMed, 2020

    PMID 32862574 6 Zitationen (Europe PMC) Quelle: OpenAlex

  41. Relationship between the Size and Location of the Mass and Hilar and Mediastinal Lymph Node Metastasis in Early and Locally Advanced Non-small Cell Lung Cancer

    Journal of College of Physicians And Surgeons Pakistan, 2020

    DOI 10.29271/jcpsp.2020.02.172 PMID 32036826 7 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  42. The relationship between FDG PET/CT-defined metabolic parameters and the histopathological subtype of oesophageal carcinomas

    Polish Journal of Radiology, 2020

    DOI 10.5114/pjr.2020.95945 PMID 32612724 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  43. Prognostic Effect of Albumin-Bilirubin Grade on Survival in Advance Gastric Cancer Patients with de-novo Liver Metastasis

    Journal of Oncological Sciences, 2020

    DOI 10.37047/jos.2020-77649 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  44. Contrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective study

    International Journal of Clinical Oncology, 2020

    DOI 10.1007/s10147-020-01729-3 PMID 32591963 3 Zitationen (Europe PMC) Quelle: OpenAlex

  45. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey.

    PubMed, 2020

    PMID 33099930 5 Zitationen (Europe PMC) Quelle: OpenAlex

  46. Targeted next-generation sequencing as a diagnostic tool in gastrointestinal system cancer/polyposis patients

    Tumori Journal, 2020

    DOI 10.1177/0300891620919171 PMID 32390558 2 Zitationen (Europe PMC) Quelle: OpenAlex

  47. Third-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Study

    Journal of Oncological Sciences, 2020

    DOI 10.37047/jos.2020-75080 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  48. Stage I colon cancer that spreads into a colovesical fistula-mediated bladder due to crohn's disease: A case report

    Current Problems in Cancer Case Reports, 2020

    DOI 10.1016/j.cpccr.2020.100010 Frei zugänglicher VolltextQuelle: OpenAlex

  49. Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.tps1107 Quelle: OpenAlex

  50. Pandemi Döneminde Kanser Klinik Araştırmaları

    Türkiye Klinikleri COVID - 19, 2020

    Quelle: OpenAlex